Please login to the form below

Not currently logged in
Email:
Password:

venous thromboembolism

This page shows the latest venous thromboembolism news and features for those working in and with pharma, biotech and healthcare.

FDA panel undermines Lilly and Incyte’s baricitinib hopes

FDA panel undermines Lilly and Incyte’s baricitinib hopes

baricitinib’s potential to cause side effects such as pulmonary embolism and venous thromboembolism.

Latest news

More from news
Approximately 3 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Case study: Using avatar technology to reduce VTE

    that occur each year from venous thromboembolism (VTE). ... Venous thromboembolism (VTE) or hospital acquired blood clots kill more people in the UK each year than MRSA, breast cancer, road traffic accidents and AIDS combined.

  • Stopping clots, saving lives

    The PR agency managed to carefully involve local hospital managers and clinicians, which I believe had a huge impact on local motivation to drive for venous thromboembolism prevention.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • NOAC Education: Empowering Stroke Prevention

    of thromboembolism. ... Prophylactic anticoagulation is also being explored in conditions such as embolic strokes of undetermined source (ESUS) or when there is a risk of a patient developing venous thromboembolism (VTE).

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics